Alder Biopharmaceuticals, Inc.
(NASDAQ : ALDR)

( )
ALDR PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
0.56%297.201.4%$596.31m
AMGNAmgen, Inc.
0.44%233.841.3%$498.51m
GILDGilead Sciences, Inc.
0.22%67.081.0%$356.60m
REGNRegeneron Pharmaceuticals, Inc.
0.56%367.672.6%$292.07m
VRTXVertex Pharmaceuticals, Inc.
0.41%220.271.9%$272.17m
ILMNIllumina, Inc.
0.11%326.943.5%$235.54m
CLVSClovis Oncology, Inc.
12.98%12.1014.7%$219.20m
ARWRArrowhead Pharmaceuticals, Inc.
4.56%70.8611.5%$213.63m
ALXNAlexion Pharmaceuticals, Inc.
-1.14%111.202.0%$196.66m
EXASEXACT Sciences Corp.
1.32%85.3024.0%$166.59m
AAgilent Technologies, Inc.
1.61%82.931.6%$155.82m
GBTGlobal Blood Therapeutics, Inc.
1.12%75.956.0%$134.81m
SRPTSarepta Therapeutics, Inc.
0.40%106.1714.6%$133.20m
BOLDAudentes Therapeutics, Inc.
0.32%59.511.4%$132.22m
BLUEbluebird bio, Inc.
11.87%85.6914.2%$130.86m

Company Profile

Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers, develops and commercializes various therapeutic antibodies. Its product portfolio includes ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine; and Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6. The company was founded by Randall C. Schatzman, Mark J. Litton, and John A. Latham in January 2004 and is headquartered in Bothell, WA.